Biotech | January 05, 2022
Biogen exercises option with Ionis for spinal muscular atrophy
Biogen paid Ionis a US $ 60 million one-time upfront payment
Biogen paid Ionis a US $ 60 million one-time upfront payment
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
The test kit is compatible with all standard Real-Time PCR machines with a test run time of 85 minutes. The result turnaround time, including sample collection and RNA extraction, is 130 minutes
Doxycycline Hyclate Delayed Release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Partnering to build biosynthesis processes and a pharmaceutical production platform
Subscribe To Our Newsletter & Stay Updated
